Actinium Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>AP</div>
ATNM -- USA Stock  

USD 10.84  0.44  4.23%

Actinium Pharmaceuticals Tangible Asset Value is relatively stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 13.82 Million. Working Capital is expected to hike to about 6.6 M this year, although the value of Earnings before Tax will most likely fall to (23.6 M). While some of us are becoming more passionate about healthcare space, it makes sense to summarize Actinium Pharmaceuticals in greater detail. Why are we still confident in hope for a quick recovery. This post is to show some fundamental factors affecting Actinium Pharmaceuticals' products and services. I will also reveal how it may impact the investing outlook for the firm in December.
Published over a month ago
View all stories for Actinium Pharmaceuticals | View All Stories
Should you hold on to your Actinium Pharmaceuticals position?
About 14.0% of Actinium Pharmaceuticals shares are held by institutions such as insurance companies. Insiders ownership of Actinium Pharmaceuticals refers to the amount of Actinium Pharmaceuticals equity owned by Actinium officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Actinium, including its current ownership diagnostics.

How important is Actinium Pharmaceuticals's Liquidity

Actinium Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Actinium Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Actinium Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Actinium Pharmaceuticals's total debt and its cash.

How Actinium utilizes its cash?

To perform a cash flow analysis of Actinium Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Actinium Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Actinium Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Actinium Pharmaceuticals Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (23.16 Million)

What did Actinium Pharmaceuticals file with SEC?

The SEC filings are financial statements or other formal documents of Actinium Pharmaceuticals that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database. Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Actinium shareholders may or may not be submitted as SEC does not always require it.
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
Unclassified Corporate Event
View
Other Events
View
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Actinium shareholders may or may not be submitted as SEC does not always require it.

Breaking it down a bit more

The market capitalization of Actinium Pharmaceuticals is $151.22 Million. Almost 85.0 percent of Actinium Pharmaceuticals outstanding shares are held by regular investors with 0.9 (percent) owned by insiders and only 13.9 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Ownership Breakdown

Retail Investors
85.2%
Institutions
13.9%
Retail Investors85.2
Insiders0.9
Institutions13.9

Will Actinium stakeholders exit after the pull down?

New risk adjusted performance indicator falls down to -0.12. Possible price surge? Actinium Pharmaceuticals exhibits very low volatility with skewness of -1.23 and kurtosis of 4.06. However, we advise investors to further study Actinium Pharmaceuticals technical indicators to make sure all market info is available and is reliable.

Our Final Take On Actinium Pharmaceuticals

While some other firms in the biotechnology industry are either recovering or due for a correction, Actinium may not be as strong as the others in terms of longer-term growth potentials. To sum up, as of the 1st of November 2020, our current 30 days buy-or-sell advice on the company is Hold. We believe Actinium Pharmaceuticals is undervalued with very low chance of bankruptcy for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Actinium Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com